证券代码：688136 证券简称：科兴制药 公告编号：2025-058 科兴生物制药股份有限公司 关于召开2025年第一次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2025年第一次临时股东大会 召开日期时间：2025 年 8 月 29 日 14 点 00 分 召开地点：深圳市南山区高新中一道与科技中一路交汇处创益科技大厦 B 栋 19 楼会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 8 月 29 日 至2025 年 8 月 29 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 股东大会召开日期：2025年8月29日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 （二） 股东大会召集人：董事会 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结 合的方式 （四） 现场会议召开 ...

Investment Rating - The report indicates a focus on potential business development opportunities in the weight loss drug sector, suggesting a positive outlook for innovative drug companies in this area [1][2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.84% from August 4 to August 8, underperforming compared to the Wind All A index (1.94%) and the CSI 300 index (1.23%) [7][9]. - Notable sub-sectors that performed well include medical consumables (3.93%), in vitro diagnostics (2.55%), and medical devices (1.94%), while medical research outsourcing (-3.56%), chemical preparations (-2.04%), and traditional Chinese medicine (-1.88%) saw significant declines [8][10]. - The report highlights the competitive landscape in the weight loss drug pipeline, with Eli Lilly reaffirming the feasibility of oral GLP-1 drugs, while other multinational corporations (MNCs) may seek external products to enhance competitiveness [2][12]. - The report also discusses the initiative by seven government departments to promote innovation in the brain-computer interface industry, aiming for breakthroughs in key technologies by 2027 [2][12]. Summary by Sections Market Weekly Review - The pharmaceutical and biotechnology sector saw a decline of 0.84% during the week, with significant internal rotation and underperformance compared to broader indices [7][9]. - Medical consumables, in vitro diagnostics, and medical devices were the top-performing sub-sectors, while medical research outsourcing and chemical preparations faced the largest declines [8][10]. Industry News and Key Company Announcements - The report notes several key industry events, including the approval of a biosimilar drug by Boan Biotech and the joint initiative by multiple government departments to foster the brain-computer interface industry [11][12]. - Significant company announcements include the approval of new indications for existing drugs and the launch of new products, indicating ongoing innovation within the sector [15][16].

Core Viewpoint - The current valuation of the pharmaceutical sector is at a low level, with public funds (excluding pharmaceutical funds) having low allocation to the sector. Considering the positive recovery of macroeconomic factors such as US Treasury rates, the industry is expected to experience growth by 2025, with various investment opportunities emerging [12][20]. Market Review - The CITIC Pharmaceutical Index decreased by 0.79%, underperforming the CSI 300 Index by 2.02 percentage points, ranking last among 30 primary industries [9]. - The top ten stocks by increase this week included Nanxin Pharmaceutical, Haichen Pharmaceutical, and Sainuo Medical, with increases ranging from 22.45% to 42.48%. Conversely, the top ten stocks by decrease included Nanmo Biological and Qizheng Tibetan Medicine, with decreases ranging from -13.50% to -16.11% [6][9]. Industry and Stock Events - The brain-computer interface (BCI) market is expected to grow significantly, with the global market size projected to increase from $1.2 billion in 2019 to $7.63 billion by 2029, reflecting a CAGR of 25.2% [20][21]. - In China, the BCI market is anticipated to grow from 1 billion yuan in 2020 to 10.5 billion yuan by 2029, with a CAGR of 35.5% [20][22]. - Non-invasive BCIs currently dominate the market, accounting for 78% of the global BCI market share, while medical applications represent over 60% of the downstream application scenarios [15][16]. Investment Themes - The pharmaceutical industry is expected to see a shift from quantity to quality in the innovative drug sector, emphasizing differentiated and internationalized pipelines by 2025 [12]. - The medical device sector is witnessing a recovery in bidding volumes for imaging equipment, with a focus on home medical devices and orthopedic procurement [12]. - The innovation chain (CXO + life sciences services) is anticipated to experience a rebound in investment, with a gradual return to high growth by 2025 [12]. Brain-Computer Interface Industry Update - The BCI industry is characterized by three main types: invasive, semi-invasive, and non-invasive, with non-invasive being the most prevalent due to its safety and ease of use [17][18]. - The Chinese BCI market is still in its early stages, with many companies yet to enter a competitive phase, and the clinical registration numbers are led by companies like Pinchi Medical and Zhejiang Yiyang [29][30]. Policy Support - National and local policies are increasingly supporting the BCI industry, with various departments releasing guidelines to promote innovation and application in the field [23][24].

Core Insights - The animal vaccine sector saw a rise of 1.41%, ranking 8th among concept sectors, with 15 stocks increasing in value, led by Shenlian Bio, Kanghua Bio, and Tiankang Bio, which rose by 9.71%, 8.60%, and 2.02% respectively [1][2] - The sector experienced a net outflow of 6.53 million yuan in capital, with seven stocks receiving net inflows, primarily led by Guoyao Modern, which saw a net inflow of 29.79 million yuan [2][3] - The top three stocks by net inflow ratio were Guoyao Modern at 17.35%, Kexing Pharmaceutical at 9.18%, and Luoniushan at 9.02% [3] Stock Performance - Guoyao Modern had a daily increase of 1.35% with a turnover rate of 1.14% and a net capital flow of 29.79 million yuan [3] - Kexing Pharmaceutical increased by 0.54% with a turnover rate of 2.79% and a net capital flow of 24.08 million yuan [3] - Luoniushan rose by 1.11% with a turnover rate of 2.44% and a net capital flow of 16.07 million yuan [3] Declining Stocks - Xianfeng Holdings, Biotech Shares, and Yongshun Bio were among the stocks with the largest declines, falling by 3.05%, 1.04%, and 0.60% respectively [1][4] - Other notable declines included Tian Kang Bio at 2.02% and Ruipu Bio at 0.56% [4]

Group 1 - The closing price of Sinovac Biotech on August 6 was 47.75 yuan, down 1.38 yuan or 2.81% from the previous trading day [1] - The trading volume on that day was 94,500 lots, with a total transaction amount of 456 million yuan [1] - Sinovac Biotech is an innovative company focused on the biopharmaceutical field, primarily engaged in the research, development, production, and sales of recombinant protein drugs and microbiome preparations [1] Group 2 - The company's products cover areas such as antiviral, hematology, oncology and immunology, and degenerative diseases [1] - Recently, the company established a comprehensive strategic partnership with IQVIA to jointly advance the clinical design, registration, and commercialization of Sinovac's innovative drugs and biosimilars in Europe and globally [1] - On August 6, the net outflow of main funds was 9.44 million yuan, while the net inflow over the past five days was 34.86 million yuan [1]

Core Viewpoint - Kexing Biopharmaceutical Co., Ltd. has successfully passed the AEO advanced certification audit, enhancing its credibility and operational efficiency in international trade, particularly in the high-end biopharmaceutical market [1][3]. Group 1: Company Overview - Kexing Biopharmaceutical is an innovative biopharmaceutical company with over 20 years of international experience, selling products in more than 70 countries and regions [1]. - The company is currently exporting erythropoietin injection worth 12.13 million yuan to Brazil, highlighting its active role in the global market [1]. Group 2: Challenges and Solutions - The company faces stringent requirements for cold chain logistics, needing to maintain a temperature of 2-8°C during transport, where even an additional hour in transit increases logistics costs and risks of product efficacy [1]. - The local customs authority has recognized the company's needs and has taken proactive measures to support it, including forming a specialized team to assist with AEO certification [3]. Group 3: Benefits of AEO Certification - Following AEO certification, the company has experienced a significant reduction in inspection rates and expedited customs clearance, reducing the transport time for shipments to Brazil from 7 days to approximately 5 days [3]. - The AEO certification has provided tangible benefits, including lower logistics costs, enhanced product competitiveness, and improved patient medication safety [3]. Group 4: Industry Impact - The AEO certification is seen as a key driver for high-quality foreign trade development, with the local customs authority implementing a comprehensive support system for businesses [3]. - In the first half of the year, Jinan added three new AEO certified enterprises, bringing the total to 27, which collectively accounted for over 40% of the city's total import and export value, underscoring their importance in stabilizing and enhancing the local foreign trade landscape [3].

Core Viewpoint - The company, Sinovac Biotech, has established a comprehensive strategic partnership with IQVIA to enhance the clinical design, registration, and commercialization of its innovative drugs and biosimilars in Europe and globally [1] Group 1 - The partnership aims to leverage the strengths of both companies to advance the development of Sinovac's products [1] - The collaboration will focus on the clinical design and registration processes, indicating a commitment to regulatory compliance and market readiness [1] - The strategic alliance is expected to facilitate the commercialization of Sinovac's innovative drugs and biosimilars, potentially increasing market access and revenue opportunities [1]

Core Viewpoint - The announcement details the results of a share transfer by Shenzhen Koyi Pharmaceutical Holdings Co., Ltd., which is the controlling shareholder of Kexing Biopharmaceutical Co., Ltd. The transfer involves a reduction in the shareholding percentage of Koyi Pharmaceutical and its concerted actor, Deng Xueqin, from 63.89% to 60.38% after the transfer of 6,037,717 shares at a price of 36.70 yuan per share [2][4][9]. Group 1 - The share transfer price is set at 36.70 yuan per share, with a total of 6,037,717 shares being transferred [2]. - The controlling shareholder, Koyi Pharmaceutical, is involved in this share transfer [3]. - The transfer results in a passive dilution of shares, and there will be no change in the company's controlling shareholder or actual controller [4]. Group 2 - As of July 30, 2025, Koyi Pharmaceutical held more than 5% of the company's shares and is the controlling shareholder, which is controlled by Deng Xueqin [5]. - Koyi Pharmaceutical and Deng Xueqin are in a concerted action relationship [6]. - Following the share transfer, Koyi Pharmaceutical and Deng Xueqin's combined shareholding will decrease from 63.89% to 60.38% [8]. Group 3 - The total share capital of the company increased from 199,642,250 shares to 201,257,250 shares due to the completion of the first vesting period of the 2024 restricted stock incentive plan [8]. - The share transfer on August 5, 2025, accounted for 3.00% of the company's total share capital [9]. - The transfer process involved 95 institutional investors, with 14 valid bids received during the subscription period [12].

Core Viewpoint - The announcement details the results of a share transfer by Shenzhen Keyi Pharmaceutical Holdings Co., Ltd., which is the controlling shareholder of Kexing Pharmaceutical Co., Ltd. The transfer involves 6,037,717 shares at a price of 36.70 yuan per share, leading to a dilution of the controlling shareholder's stake from 63.89% to 60.38% [1][3]. Group 1: Transfer Details - The share transfer price is set at 36.70 yuan per share, with a total of 6,037,717 shares being transferred [1]. - The controlling shareholder, Keyi Pharmaceutical, is involved in this transfer, which is classified as a passive dilution and will not change the actual controller of the company [1][5]. - After the transfer, Keyi Pharmaceutical and its concerted actor, Deng Xueqin, will hold a total of 121,515,555 shares, reducing their ownership percentage from 63.89% to 60.38% [2][3]. Group 2: Shareholder Information - Keyi Pharmaceutical is the controlling shareholder and is controlled by Deng Xueqin, who is also the chairman of the company [2]. - The total share capital of the company increased from 199,642,250 shares to 201,257,250 shares due to this transfer [2]. - The ownership percentage of Keyi Pharmaceutical and its concerted actor will decrease from 63.89% to 60.38% following the transfer [3]. Group 3: Regulatory Compliance - The share transfer process was reviewed by China International Capital Corporation, which confirmed that it adhered to fair and just principles and complied with relevant securities market regulations [5]. - The transfer process followed the guidelines set forth by various laws and regulations, ensuring compliance with the requirements for share transfers in the market [5].

证券代码：688136 证券简称：科兴制药 公告编号：2025-057 科兴生物制药股份有限公司 股东询价转让结果报告书暨持股 5%以上股东权益变动 触及 1%整数倍的提示性公告 深圳科益医药控股有限公司（以下简称"科益医药"或"转让方"）及其一致行动 人邓学勤保证向科兴生物制药股份有限公司（以下简称"公司"或"科兴制药"）提供 的信息真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 本次询价转让的价格为36.70元/股，转让的股票数量为6,037,717股。 公司控股股东参与本次询价转让。 本次权益变动为被动稀释、询价转让，本次转让不会导致公司控股股东、 实际控制人发生变化。 本次询价转让完成后，科益医药及其一致行动人邓学勤先生合计持有本 公司 121,515,555 股股份，占公司总股本的比例由权益变动前的由63.89%减少至 60.38%，累计权益变动比例触及 1%的整数倍。 一、 转让方情况 (一)转让方基本情况 本次询价转让的转让方科益医药持有公司股份比例超过 5%，为公司控股 股东，系公司实际控制人、董事长邓学 ...